Back to Journals » Therapeutics and Clinical Risk Management » Volume 4 » Issue 5

Evaluation of extended and continuous use oral contraceptives

Authors Kristen Page Wright, Julia V Johnson

Published 10 October 2008 Volume 2008:4(5) Pages 905—911

DOI https://doi.org/10.2147/TCRM.S2143

Kristen Page Wright, Julia V Johnson

University of Vermont College of Medicine and Reproductive Endocrinology and Infertility, Women’s Health Care Services, Fletcher Allen Health Care, Burlington, VT USA

Abstract: Oral contraceptives are classically given in a cyclic manner with 21 days of active pills followed by 7 days of placebo. In the past 4 years, new oral contraceptives have been introduced which either shorten the placebo time, lengthen the active pills (extended cycle), or provide active pills every day (continuous). These concepts are not new; extended and continuous pills were first studied in the 1960s and 1970s and have been provided in an off-label manner by gynecologists to treat menstrual disorders, such as menorrhagia and dysmenorrhea, and gynecologic disorders, such as endometriosis. Now that extended and continuous combined oral contraceptives are available for all patients, it is critical for providers to understand the physiology, dosing, side effects, and benefits of this form of oral contraceptive. This article reviews the history and the potential uses of the new continuous combined oral contraceptive.

Keywords: oral contraceptives, administration, dosage, adverse effects, menstrual disturbances

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] 

 

Readers of this article also read:

Spinal pain: current understanding, trends, and the future of care

Parkin-Smith GF, Amorin-Woods LG, Davies SJ, Losco BE, Adams J

Journal of Pain Research 2015, 8:741-752

Published Date: 23 October 2015

Preservative-free tafluprost in the treatment of naive patients with glaucoma and ocular hypertension

Lanzl I, Hamacher T, Rosbach K, Ramez MO, Rothe R, Růžičková E, Karhanová M, Kimmich F

Clinical Ophthalmology 2013, 7:901-910

Published Date: 16 May 2013

An analysis of the Bateson Review of research using nonhuman primates

Greek R, Hansen LA, Menache A

Medicolegal and Bioethics 2011, 1:3-22

Published Date: 6 December 2011

Management of preterm labor: atosiban or nifedipine?

Roel de Heus, Eduard J H Mulder, Gerard H A Visser

International Journal of Women's Health 2010, 2:137-142

Published Date: 17 May 2010

Spontaneous bacterial peritonitis: How to deal with this life-threatening cirrhosis complication?

Tarsila CR Ribeiro, Julio MF Chebli, Mario Kondo, Pedro Duarte Gaburri, Liliana Andrade Chebli, Ana Cristina Amaral Feldner

Therapeutics and Clinical Risk Management 2008, 4:919-925

Published Date: 10 October 2008

Multi-targeted approach in the treatment of thyroid cancer

Scott N Pinchot, Rebecca S Sippel, Herbert Chen

Therapeutics and Clinical Risk Management 2008, 4:935-947

Published Date: 10 October 2008